Compare LMNR & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMNR | IMUX |
|---|---|---|
| Founded | 1893 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.0M | 209.2M |
| IPO Year | 2005 | 2013 |
| Metric | LMNR | IMUX |
|---|---|---|
| Price | $13.30 | $14.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $20.00 | ★ $36.00 |
| AVG Volume (30 Days) | 104.5K | ★ 182.6K |
| Earning Date | 06-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $159,723,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.67 | $0.51 |
| 52 Week High | $16.62 | $15.84 |
| Indicator | LMNR | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 53.88 | 58.08 |
| Support Level | $12.54 | $0.74 |
| Resistance Level | $13.65 | $15.81 |
| Average True Range (ATR) | 0.39 | 0.90 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 58.13 | 40.69 |
Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.